纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | CHRNa2 |
Uniprot No | Q15822 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-529aa |
氨基酸序列 | MGPSCPVFLSFTKLSLWWLLLTPAGGEEAKRPPPRAPGDPLSSPSPTALPQGGSHTETEDRLFKHLFRGYNRWARPVPNTSDVVIVRFGLSIAQLIDVDEKNQMMTTNVWLKQEWSDYKLRWNPTDFGNITSLRVPSEMIWIPDIVLYNNADGEFAVTHMTKAHLFSTGTVHWVPPAIYKSSCSIDVTFFPFDQQNCKMKFGSWTYDKAKIDLEQMEQTVDLKDYWESGEWAIVNATGTYNSKKYDCCAEIYPDVTYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSDCGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPSTHTMPHWVRGALLGCVPRWLLMNRPPPPVELCHPLRLKLSPSYHWLESNVDAEEREVVVEEEDRWACAGHVAPSVGTLCSHGHLHSGASGPKAEALLQEGELLLSPHMQKALEGVHYIADHLRSEDADSSVKEDWKYVAMVIDRIFLWLFIIVCFLGTIGLFLPPFLAGMI |
预测分子量 | 59,7 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHRNA2重组蛋白的模拟参考文献示例,涵盖不同研究方向:
---
1. **标题**: "Functional Expression of Recombinant CHRNA2 in Xenopus Oocytes Reveals Altered Pharmacological Properties"
**作者**: Tanaka M, et al.
**摘要**: 研究在非洲爪蟾卵母细胞中表达了重组CHRNA2蛋白,利用双电极电压钳技术证明其与β4亚基共表达时,对尼古丁的敏感性显著高于其他亚型组合,提示亚基特异性功能差异。
2. **标题**: "Cryo-EM Structure of the Human CHRNA2/LYNX1 Complex Modulates Ion Channel Gating"
**作者**: Chen H, et al.
**摘要**: 通过冷冻电镜解析CHRNA2重组蛋白与调控蛋白LYNX1的复合物结构,揭示了LYNX1如何通过结合胞外域变构调节离子通道的门控动力学,为神经信号调控机制提供新见解。
3. **标题**: "High-Yield Production of CHRNA2 Recombinant Protein in Insect Cells for Autoantibody Detection in Myasthenia Gravis"
**作者**: Rossi S, et al.
**摘要**: 开发基于杆状病毒系统的CHRNA2重组蛋白高效表达方法,应用于重症肌无力患者血清中特异性自身抗体的检测,显著提升诊断灵敏度。
4. **标题**: "CHRNA2 Knockout Mice with Recombinant Protein Rescue Exhibit Deficits in Auditory Processing"
**作者**: Kim T, et al.
**摘要**: 构建CHRNA2基因敲除小鼠模型,并通过脑室内注射重组蛋白部分恢复听觉皮层突触传递异常,证实CHRNA2在内源性听觉通路中的关键作用。
---
*注:以上文献为示例性内容,实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实发表论文。*
**Background of CHRNA2 Recombinant Protein**
The CHRNA2 gene encodes the α2 subunit of neuronal nicotinic acetylcholine receptors (nAChRs), a family of ligand-gated ion channels critical for synaptic transmission and neuromodulation. These receptors are composed of five subunits arranged around a central pore, with α2-containing receptors typically forming heteromeric complexes (e.g., α2β4) or, less commonly, homomeric configurations. nAChRs are widely expressed in the central and peripheral nervous systems, playing roles in cognitive functions, neurotransmitter release, and neural plasticity.
CHRNA2 has garnered attention due to its association with neurological and psychiatric disorders. Genetic studies link CHRNA2 variants to epilepsy, schizophrenia, and attention-deficit/hyperactivity disorder (ADHD), highlighting its importance in maintaining excitatory-inhibitory balance. The α2 subunit’s specific contribution to receptor kinetics, calcium permeability, and ligand sensitivity remains an active area of research, particularly in understanding how mutations disrupt neural circuits.
Recombinant CHRNA2 protein is produced using expression systems like *E. coli* or mammalian cell lines (e.g., HEK293), enabling controlled study of its structure-function relationships. Purified recombinant proteins facilitate *in vitro* assays, drug screening, and antibody development. They are essential for characterizing receptor pharmacology, mapping binding sites for toxins or therapeutics (e.g., nicotine, varenicline), and studying pathogenic mutations.
Advances in structural biology, such as cryo-EM, have utilized recombinant CHRNA2 to resolve receptor architectures, providing insights into gating mechanisms and allosteric modulation. This protein also serves as a tool for developing targeted therapies for nAChR-related disorders. Overall, CHRNA2 recombinant proteins are vital for bridging genetic findings to functional and translational research in neurobiology.
(Word count: 248)
在生物科技领域,蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者,凭借自身卓越的研发实力,每年能成功研发 1000 多种全新蛋白,在重组蛋白领域不断突破。 在重组蛋白生产过程中,艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白,到具有特定催化功能的酶、参与信号传导的激酶,再到用于免疫研究的病毒抗原,艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统,昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势,能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求,从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品,更是从源头到终端的一站式解决方案。从最初的基因合成,精准地构建出符合要求的基因序列,到载体构建,为蛋白表达创造适宜的环境,再到蛋白质表达和纯化,每一个环节都严格把控。我们充分尊重客户的个性化需求,在表达 / 纯化标签的选择、表达宿主的确定等方面,为客户量身定制专属方案。 同时,艾普蒂还配备了多种纯化体系,能够应对不同特性蛋白的纯化需求。这种灵活性和专业性,极大地提高了蛋白表达和纯化的成功率,让客户的研究项目得以顺利推进,在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台,包括: 哺乳动物细胞表达平台:利用哺乳动物细胞精准修饰蛋白,产出与天然蛋白相似的重组蛋白,用于药物研发、细胞治疗等。 杂交瘤开发平台:通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株,优化后的技术让抗体亲和力与特异性更高,应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台:FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞;Beacon® 基于微流控技术,单细胞水平捕获、分析 B 细胞,挖掘抗体多样性,缩短开发周期。 凭借这些平台,艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务,推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富,拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上,艾普蒂生物不仅经验老到,还积累了详实的成功案例。针对客户的工业化生产需求,我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节,对重组蛋白基因序列进行优化,全面探索多种条件,精准找出最契合客户需求的生产方法。 此外,公司还配备了自有下游验证平台,可对重组蛋白展开系统的质量检测与性能测试,涵盖蛋白互作检测、活性验证、内毒素验证等,全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发,确保生产出的蛋白质具备所需的纯度、稳定性与生物活性,这对于保障药物的安全性和有效性起着关键作用 ,与艾普蒂生物共同推动着行业的发展。
×